ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

NCT02362048 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: ACP-196
DRUG: ACP-196 in combination with pembrolizumab

Sponsor

Acerta Pharma BV

Collaborators

[object Object]